This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ligand (LGND) Down 9.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand Sells Promacta Rights for $827M, Updates '19 View
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?
by Zacks Equity Research
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.
Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.
Ligand Pharmaceuticals (LGND) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 33.86% and 10.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales
by Zacks Equity Research
Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.
Ligand (LGND) Takes a Hit on Citron's Negative Research Report
by Zacks Equity Research
Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.
Why Is Ligand (LGND) Down 14.9% Since Last Earnings Report?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
by Zacks Equity Research
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
Ligand Pharmaceuticals (LGND) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 33.33% and 7.22%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Ligand Pharmaceuticals (LGND) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed at $168.87 in the latest trading session, marking a +1.13% move from the prior day.
Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed at $202.59 in the latest trading session, marking a -1.5% move from the prior day.
bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA
by Zacks Equity Research
bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
VistaGen Up on Fast Track Designation to Pain Candidate
by Zacks Equity Research
VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
5 Stocks With High Net Income Ratio to Scoop Up
by Zacks Equity Research
Profitability analysis is one of the best ways to evaluate the prospects of a company
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
by Zacks Equity Research
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
Medicines Company to Continue Inclisiran Studies as Planned
by Zacks Equity Research
The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.
Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara
by Zacks Equity Research
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.